United States - English - NLM (National Library of Medicine)

bryant ranch prepack - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c) - morphine sulfate 15 mg - morphine sulfate extended-release tablets are indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. limitations of use - because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations [see warnings and precautions (5.1)] , reserve morphine sulfate extended-release tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. - morphine sulfate extended-release tablets are not indicated as an as-needed (prn) analgesic. morphine sulfate extended-release tablets are contraindicated in patients with: - significant respiratory depression [see warnings and precautions (5.3)] - acute or severe bronchial

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c) - morphine sulfate 100 mg - morphine sulfate extended-release tablets are indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. limitations of use - because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations [see warnings and precautions (5.1)] , reserve morphine sulfate extended-release tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. - morphine sulfate extended-release tablets are not indicated as an as-needed (prn) analgesic. morphine sulfate extended-release tablets are contraindicated in patients with: - significant respiratory depression [see warnings and precautions (5.3)] - acute or severe bronchial

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c) - morphine sulfate 30 mg - morphine sulfate tablets are indicated for the management of acute and chronic pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. limitations of use: because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings and precautions (5.1)] , reserve morphine sulfate tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: morphine sulfate tablets are contraindicated in patients with: risk summary: prolonged use of opioid analgesics during pregnancy can cause neonatal opioid withdrawal syndrome [see warnings and precautions (5.4)]. there are no available data with morphine sulfate tablets in pregnant women to inform a drug-associated risk for major birth defects and miscarriage. published studies with morphine use during pregnancy have not reported a clear association with morphine and major birth defects [see human data]. in published animal rep

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

jurox pty limited - apomorphine hydrochloride - oral tablet - apomorphine hydrochloride alkaloid active 6.5 mg/tb - central nervous system - dog | bitch | castrate | puppy - emetic | induce vomiting

New Zealand - English - Medsafe (Medicines Safety Authority)

juno pharmaceuticals nz limited - morphine hydrochloride trihydrate 10 mg/ml equivalent to morphine base 7.58 mg/ml - solution for injection - 10 mg/ml - active: morphine hydrochloride trihydrate 10 mg/ml equivalent to morphine base 7.58 mg/ml excipient: hydrochloric acid water for injection - morphine hydrochloride is indicated for: - the relief of moderate to severe pain not responsive to non-opioid analgesics - symptomatic relief of severe and intractable pains of various categories, in terminal cancer patients - use as a pre-operative medication and as an analgesic adjunct in general anaesthesia

New Zealand - English - Medsafe (Medicines Safety Authority)

juno pharmaceuticals nz limited - morphine hydrochloride trihydrate 20 mg/ml equivalent to morphine base 15.18 mg/ml - solution for injection - 100 mg/5ml - active: morphine hydrochloride trihydrate 20 mg/ml equivalent to morphine base 15.18 mg/ml excipient: hydrochloric acid water for injection - morphine hydrochloride is indicated for: - the relief of moderate to severe pain not responsive to non-opioid analgesics - symptomatic relief of severe and intractable pains of various categories, in terminal cancer patients - use as a pre-operative medication and as an analgesic adjunct in general anaesthesia

New Zealand - English - Medsafe (Medicines Safety Authority)

juno pharmaceuticals nz limited - morphine hydrochloride trihydrate 20 mg/ml equivalent to morphine base 15.18 mg/ml - solution for injection - 20 mg/ml - active: morphine hydrochloride trihydrate 20 mg/ml equivalent to morphine base 15.18 mg/ml excipient: hydrochloric acid water for injection - morphine hydrochloride is indicated for: - the relief of moderate to severe pain not responsive to non-opioid analgesics - symptomatic relief of severe and intractable pains of various categories, in terminal cancer patients - use as a pre-operative medication and as an analgesic adjunct in general anaesthesia

New Zealand - English - Medsafe (Medicines Safety Authority)

juno pharmaceuticals nz limited - morphine hydrochloride trihydrate 10 mg/ml equivalent to morphine base 7.58 mg/ml - solution for injection - 50 mg/5ml - active: morphine hydrochloride trihydrate 10 mg/ml equivalent to morphine base 7.58 mg/ml excipient: hydrochloric acid water for injection - morphine hydrochloride is indicated for: - the relief of moderate to severe pain not responsive to non-opioid analgesics - symptomatic relief of severe and intractable pains of various categories, in terminal cancer patients - use as a pre-operative medication and as an analgesic adjunct in general anaesthesia

United States - English - NLM (National Library of Medicine)

watson laboratories, inc. - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c) - tablet, film coated, extended release - 100 mg - morphine sulfate extended-release tablets are a controlled release oral morphine formulation indicated for the relief of moderate to severe pain. they are intended for use in patients who require repeated dosing with potent opioid analgesics over periods of more than a few days. morphine sulfate extended-release is contraindicated in patients with known hypersensitivity to the drug, in patients with respiratory depression in the absence of resuscitative equipment, and in patients with acute or severe bronchial asthma. morphine sulfate extended-release is contraindicated in any patient who has or is suspected of having a paralytic ileus. opioid analgesics may cause psychological and physical dependence (see warnings). physical dependence results in withdrawal symptoms in patients who abruptly discontinue the drug or may be precipitated through the administration of drugs with narcotic antagonist activity, e.g., naloxone or mixed agonist/antagonist analgesics (pentazocine, etc.; see also overdosage). physical d

United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c) - morphine sulfate 60 mg - morphine sulfate extended-release tablets are an extended-release oral formulation of morphine sulfate indicated for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. morphine sulfate extended-release tablets are not intended for use as a prn analgesic. the morphine sulfate extended-release tablets 100 mg and 200 mg strengths are high dose, extended-release, oral morphine formulations indicated for the relief of pain in opioid-tolerant patients only. morphine sulfate extended-release tablets are not indicated for pain in the immediate postoperative period (the first 12 to 24 hours following surgery) for patients not previously taking the drug, because its safety in this setting has not been established. morphine sulfate extended-release tablets are not indicated for pain in the postoperative period if the pain is mild, or not expected to persist for an extended period of time. morphine sulfate extended-release ta